Label: PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN- propoxyphene hydrochloride and acetaminophen tablet 

  • Label RSS
  • NDC Code(s): 0591-0714-01, 0591-0714-05
  • Packager: Watson Laboratories, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: CIV
  • Marketing Status:

Drug Label Information

Updated 02/07

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Propoxyphene hydrochloride is an odorless white crystalline powder with a bitter taste. It is freely soluble in water. Chemically, it is (2S, 3R)-(+)-4-(Dimethylamino)-3-methyl-1,2-diphenyl-2-butanol propionate (ester) hydrochloride, which can be represented by the following structural formula:

    Image from Drug Label Content

    C22H29NO2•HCl    Molecular Weight: 375.93

    Acetaminophen is a white, crystalline powder, possessing a slightly bitter taste. It is soluble in boiling water and freely soluble in alcohol. Chemically, it is 4’-Hydroxyacetanilide, which can be presented by the following structural formula:

    Image from Drug Label Content

    C8H9NO2    Molecular Weight: 151.16

    Each tablet, for oral administration, contains 65 mg propoxyphene hydrochloride and 650 mg acetaminophen. In addition, each tablet contains the following inactive ingredients: corn starch, crospovidone, D&C Red No. 30 aluminum lake, D&C Yellow No. 10 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polacrillin potassium, polyethylene glycol, polysorbate 80, povidone, pregelatinized starch, stearic acid, and titanium dioxide.

    Close
  • CLINICAL PHARMACOLOGY

    Propoxyphene is a centrally acting narcotic analgesic agent. Equimolar doses of propoxyphene hydrochloride or napsylate provide similar plasma concentrations. Following administration of 65, 130, or 195 mg of propoxyphene hydrochloride, the bioavailability of propoxyphene is equivalent to that of 100, 200, or 300 mg respectively of propoxyphene napsylate. Peak plasma concentrations of propoxyphene are reached in 2 to 21/2 hours. After a 65-mg oral dose of propoxyphene hydrochloride, peak plasma levels of 0.05 to 0.1 mcg/mL are achieved. As shown in Figure 1, the napsylate salt tends to be absorbed more slowly than the hydrochloride. At or near therapeutic doses, this absorption difference is small when compared with that among subjects and among doses.

    Image from Drug Label Content

    Figure 1. Mean plasma concentrations of propoxyphene in 8 human subjects following oral administration of 65 mg and 130 mg of the hydrochloride salt, and 100 mg and 200 mg of the napsylate; and in 7 subjects given 195 mg of the hydrochloride and 300 mg of the napsylate salt.

    Because of this several hundredfold difference in solubility, the absorption rate of very large doses of the napsylate salt is significantly lower than that of equimolar doses of the hydrochloride.

    Repeated doses of propoxyphene at 6-hour intervals lead to increasing plasma concentrations, with a plateau after the ninth dose at 48 hours.

    Propoxyphene is metabolized in the liver to yield norpropoxyphene. Propoxyphene has a half-life of 6 to 12 hours, whereas that of norpropoxyphene is 30 to 36 hours.

    Norpropoxyphene has substantially less central nervous system depressant effect than propoxyphene, but a greater local anesthetic effect, which is similar to that of amitriptyline and antiarrhythmic agents, such as lidocaine and quinidine.

    In animal studies in which propoxyphene and norpropoxyphene were continuously infused in large amounts, intracardiac conduction time (PR and QRS intervals) was prolonged. Any intracardiac conduction delay attributable to high concentrations of norpropoxyphene may be of relatively long duration.

    ACTIONS

    Propoxyphene is a mild narcotic analgesic structurally related to methadone. The potency of propoxyphene hydrochloride is from two-thirds to equal that of codeine.

    Propoxyphene hydrochloride and acetaminophen provide the analgesic activity of propoxyphene hydrochloride and the antipyretic-analgesic activity of acetaminophen.

    The combination of propoxyphene and acetaminophen produces greater analgesia than that produced by either propoxyphene or acetaminophen administered alone.

    Close
  • INDICATIONS AND USAGE

    Propoxyphene hydrochloride and acetaminophen tablets are indicated for the relief of mild-to-moderate pain, either when pain is present alone or when it is accompanied by fever.

    Close
  • CONTRAINDICATIONS

    Hypersensitivity to propoxyphene or to acetaminophen.

    Close
  • WARNINGS

    Do not prescribe propoxyphene for patients who are suicidal or addiction-prone.

    Prescribe propoxyphene with caution for patients taking tranquilizers or antidepressant drugs and patients who use alcohol in excess.

    Tell your patients not to exceed the recommended dose and to limit their intake of alcohol.

    Propoxyphene products in excessive doses, either alone or in combination with other CNS depressants, including alcohol, are a major cause of drug-related deaths. Fatalities within the first hour of overdosage are not uncommon. In a survey of deaths due to overdosage conducted in 1975, in approximately 20% of the fatal cases, death occurred within the first hour (5% occurred within 15 minutes). Propoxyphene should not be taken in doses higher than those recommended by the physician. The judicious prescribing of propoxyphene is essential to the safe use of this drug. With patients who are depressed or suicidal, consideration should be given to the use of non-narcotic analgesics. Patients should be cautioned about the concomitant use of propoxyphene products and alcohol because of potentially serious CNS-additive effects of these agents. Because of its added depressant effects, propoxyphene should be prescribed with caution for those patients whose medical condition requires the concomitant administration of sedatives, tranquilizers, muscle relaxants, antidepressants or other CNS-depressant drugs. Patients should be advised of the additive depressant effects of these combinations.

    Many of the propoxyphene-related deaths have occurred in patients with previous histories of emotional disturbances or suicidal ideation or attempts, as well as histories of misuse of tranquilizers, alcohol, and other CNS-active drugs. Some deaths have occurred as a consequence of the accidental ingestion of excessive quantities of propoxyphene alone or in combination with other drugs. Patients taking propoxyphene should be warned not to exceed the dosage recommended by the physician.

    DRUG DEPENDENCE

    Propoxyphene, when taken in higher-than-recommended doses over long periods of time, can produce drug dependence characterized by psychic dependence and, less frequently, physical dependence and tolerance. Propoxyphene will only partially suppress the withdrawal syndrome in individuals physically dependent on morphine or other narcotics. The abuse liability of propoxyphene is qualitatively similar to that of codeine although quantitatively less, and propoxyphene should be prescribed with the same degree of caution appropriate to the use of codeine.

    USAGE IN AMBULATORY PATIENTS

    Propoxyphene may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car or operating machinery. The patient should be cautioned accordingly.

    Close
  • PRECAUTIONS

    GENERAL

    Propoxyphene should be administered with caution to patients with hepatic or renal impairment since higher serum concentrations or delayed elimination may occur.

    INFORMATION FOR PATIENTS

    A Patient Information Sheet is available for the product. See text following ANIMAL TOXICOLOGY section below.

    DRUG INTERACTIONS

    The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol.

    As is the case with many medicinal agents, propoxyphene may slow the metabolism of a concomitantly administered drug. Should this occur, the higher serum concentrations of that drug may result in increased pharmacologic or adverse effects of that drug. Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. Severe neurologic signs, including coma, have occurred with concurrent use of carbamazepine.

    PREGNANCY

    Safe use in pregnancy has not been established relative to possible adverse effects on fetal development. Instances of withdrawal symptoms in the neonate have been reported following usage during pregnancy. Therefore, propoxyphene should not be used in pregnant women unless, in the judgement of the physician, the potential benefits outweigh the possible hazards.

    NURSING MOTHERS

    Low levels of propoxyphene have been detected in human milk. In postpartum studies involving nursing mothers who were given propoxyphene, no adverse effects were noted in infants receiving mother's milk.

    PEDIATRIC USE

    Propoxyphene is not recommended for use in pediatric patients because documented clinical experience has been insufficient to establish safety and a suitable dosage regimen in the pediatric age group.

    USAGE IN THE ELDERLY

    The rate of propoxyphene metabolism may be reduced in some patients. Increased dosing interval should be considered.

    Close
  • ADVERSE REACTIONS

    In a survey conducted in hospitalized patients, less than 1% of patients taking propoxyphene hydrochloride at recommended doses experienced side effects. The most frequently reported were dizziness, sedation, nausea, and vomiting. Some of these adverse reactions may be alleviated if the patient lies down.

    Other adverse reactions include constipation, abdominal pain, skin rashes, light-headedness, headache, weakness, euphoria, dysphoria, hallucinations and minor visual disturbances.

    Liver dysfunction has been reported in association with both active components of propoxyphene hydrochloride and acetaminophen tablets. Propoxyphene therapy has been associated with abnormal liver-function tests and, more rarely, with instances of reversible jaundice (including cholestatic jaundice). Hepatic necrosis may result from acute overdose of acetaminophen (see OVERDOSAGE). In chronic ethanol abusers, this has been reported rarely with short-term use of acetaminophen dosages of 2.5 to 10 g/day. Fatalities have occurred.

    Renal papillary necrosis may result from chronic acetaminophen use, particularly when the dosage is greater than recommended and when combined with aspirin.

    Subacute painful myopathy has occurred following chronic propoxyphene overdosage.

    Close
  • OVERDOSAGE

    In all cases of suspected overdosage, call your regional Poison Control Center to obtain the most up-to-date information about the treatment of overdosage. This recommendation is made because, in general, information regarding the treatment of overdosage may change more rapidly than do package inserts.

    Initial consideration should be given to the management of the CNS effects of propoxyphene overdosage. Resuscitative measures should be initiated promptly.

    SYMPTOMS OF PROPOXYPHENE OVERDOSAGE

    The manifestations of acute overdosage with propoxyphene are those of narcotic overdosage. The patient is usually somnolent, but may be stuporous or comatose and convulsing. Respiratory depression is characteristic. The ventilatory rate and/or tidal volume is decreased, which results in cyanosis and hypoxia. Pupils, initially pinpoint, may become dilated as hypoxia increases. Cheyne-Stokes respiration and apnea may occur. Blood pressure and heart rate are usually normal initially, but blood pressure falls and cardiac performance deteriorates, which ultimately results in pulmonary edema and circulatory collapse unless the respiratory depression is corrected and adequate ventilation is restored promptly. Cardiac arrhythmias and conduction delay may be present. A combined respiratory-metabolic acidosis occurs owing to retained CO2 (hypercapnia) and to lactic acid formed during anaerobic glycolysis. Acidosis may be severe if large amounts of salicylates have also been ingested. Death may occur.

    TREATMENT OF PROPOXYPHENE OVERDOSAGE

    Attention should be directed first to establishing a patent airway and to restoring ventilation. Mechanically assisted ventilation, with or without oxygen, may be required, and positive-pressure respiration may be desirable if pulmonary edema is present. The narcotic antagonist naloxone will markedly reduce the degree of respiratory depression, and 0.4 to 2 mg should be administered promptly, preferably intravenously. If the desired degree of counteraction with improvement in respiratory functions is not obtained, naloxone should be repeated at 2-to-3-minute intervals. The duration of action of the antagonist may be brief. If no response is observed after 10 mg of naloxone have been administered, the diagnosis of propoxyphene toxicity should be questioned. Naloxone may also be administered by continuous intravenous infusion.

    TREATMENT OF PROPOXYPHENE OVERDOSAGE IN CHILDREN

    The usual initial dose of naloxone in children is 0.01 mg/kg body weight given intravenously. If the dose does not result in the desired degree of clinical improvement, a subsequent increased dose of 0.1 mg/kg body weight may be administered. If an IV route of administration is not available, naloxone may be administered IM or subcutaneously in divided doses. If necessary, naloxone can be diluted with Sterile Water for Injection.

    Blood gases, pH, and electrolytes should be monitored in order that acidosis and any electrolyte disturbance present may be corrected promptly. Acidosis, hypoxia, and generalized CNS depression predispose to the development of cardiac arrhythmias. Ventricular fibrillation or cardiac arrest may occur and necessitate the full complement of cardiopulmonary resuscitation (CPR) measures. Respiratory acidosis rapidly subsides as ventilation is restored and hypercapnia eliminated, but lactic acidosis may require intravenous bicarbonate for prompt correction.

    Electrocardiographic monitoring is essential. Prompt correction of hypoxia, acidosis, and electrolyte disturbance (when present) will help prevent these cardiac complications and will increase the effectiveness of agents administered to restore normal cardiac function.

    In addition to the use of narcotic antagonist, the patient may require careful titration with an anticonvulsant to control convulsions. Analeptic drugs (for example, caffeine or amphetamine) should not be used because of tendency to precipitate convulsions.

    General supportive measures, in addition to oxygen, include, when necessary, intravenous fluids, vasopressor-inotropic compounds, and when infection is likely, anti-infective agents. Gastric lavage may be useful, and activated charcoal can adsorb a significant amount of ingested propoxyphene. Dialysis is of little value in poisoning due to propoxyphene. Efforts should be made to determine whether other agents such as alcohol, barbiturates, tranquilizers, or other CNS depressants, were also ingested, since these increase CNS depression as well as cause specific toxic effects.

    SYMPTOMS OF ACETAMINOPHEN OVERDOSAGE

    Shortly after oral ingestion of an overdosage of acetaminophen and for the next 24 hours, anorexia, nausea, vomiting, diaphoresis, general malaise and abdominal pain have been noted. The patient may then present no symptoms, but evidence of liver dysfunction may become apparent up to 72 hours after ingestion, with elevated serum transaminase and lactic dehydrogenase levels, an increase in serum bilirubin concentrations, and a prolonged prothrombin time. Death from hepatic failure may result 3 to 7 days after overdosage.

    Acute renal failure may accompany the hepatic dysfunction and has been noted in patients who do not exhibit signs of fulminant hepatic failure. Typically, renal impairment is more apparent 6 to 9 days after ingestion of the overdose.

    TREATMENT OF ACETAMINOPHEN OVERDOSAGE

    Acetaminophen in massive overdosage may cause hepatic toxicity in some patients. In all cases of suspected overdose, immediately call your regional poison control center for assistance in diagnosis and for directions in the use of N-acetylcysteine as an antidote.

    In adults, hepatic toxicity has rarely been reported with acute overdoses of less than 10 g and fatalities with less than 15 g. Importantly, young children seem to be more resistant than adults to the hepatotoxic effect of an acetaminophen overdose. Despite this, the measures outlined below should be initiated in any adult or child suspected of having ingested an acetaminophen overdose.

    Because clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours postingestion, liver function studies should be obtained initially and repeated at 24-hour intervals.

    Consider emptying the stomach promptly by lavage or by induction of emesis with syrup of ipecac. Patients’ estimates of the quantity of a drug ingested are notoriously unreliable. Therefore, if an acetaminophen overdose is suspected, a serum acetaminophen assay should be obtained as early as possible, but no sooner than four hours following ingestion. The antidote, N-acetylcysteine, should be administered as early as possible, and within 16 hours of the overdose ingestion for optimal results. Following recovery, there are no residual, structural or functional hepatic abnormalities.

    Close
  • DOSAGE AND ADMINISTRATION

    The product is given orally. The usual dose is 65 mg propoxyphene hydrochloride and 650 mg acetaminophen every 4 hours as needed for pain. The maximum recommended dose of propoxyphene hydrochloride is 390 mg per day.

    Consideration should be given to a reduced total daily dosage in patients with hepatic or renal impairment.

    Close
  • HOW SUPPLIED

    Propoxyphene Hydrochloride and Acetaminophen Tablets 65 mg/650 mg are orange, oblong, unscored tablets, marked 714, and 65 over 650 on one side of the tablet and WATSON on the other side, containing 65 mg of propoxyphene hydrochloride and 650 mg of acetaminophen available in bottles of 100 and 500.

    Keep tightly closed. Protect from light. Store at controlled room temperature 15°-30°C (59°-86°F). Dispense in a tight, light-resistant container as defined in the USP.

    Close
  • ANIMAL TOXICOLOGY

    The acute lethal doses of the hydrochloride and napsylate salts of propoxyphene were determined in 4 species. The results shown in Figure 2 indicate that on a molar basis, the napsylate salt is less toxic than the hydrochloride. This may be due to the relative insolubility and retarded absorption of propoxyphene napsylate.

    FIGURE 2 ACUTE ORAL TOXICITY
    LD50 (mg/kg) ± SE
    —————————
    LD50 (mMole/kg)
    Species Propoxyphene Propoxyphene
    Hydrochloride Napsylate
    Mouse 282 ± 39 915 ± 163
    0.75 1.62
    Rat 230 ± 44 647 ± 95
    0.61 1.14
    Rabbit ca. 82 > 183
    0.22 > 0.32
    Dog ca. 100 > 183
    0.27 > 0.32

    Some indication of the relative insolubility and retarded absorption of propoxyphene napsylate was obtained by measuring plasma propoxyphene levels in 2 groups of 4 dogs following oral administration of equimolar doses of the 2 salts. As shown in Figure 3, the peak plasma concentration observed with propoxyphene hydrochloride was much higher than that obtained after administration of the napsylate salt.

    Image from Drug Label Content

    Figure 3. Plasma propoxyphene concentrations in dogs following large doses of the hydrochloride and napsylate salts.

    Although none of the animals in this experiment died, 3 of the 4 dogs given propoxyphene hydrochloride exhibited convulsive seizures during the time interval corresponding to the peak plasma levels. The 4 animals receiving the napsylate salt were mildly ataxic but not acutely ill.

    Close
  • PATIENT INFORMATION SHEET

    YOUR PRESCRIPTION FOR PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN TABLETS

    Summary

    Products containing propoxyphene are used to relieve pain.

    LIMIT YOUR INTAKE OF ALCOHOL WHILE TAKING THIS DRUG. Make sure your doctor knows if you are taking tranquilizers, sleep aids, antidepressants, antihistamines, or any other drugs that make you sleepy. Combining propoxyphene with alcohol or these drugs in excessive doses is dangerous.

    Use care while driving a car or using machines until you see how the drug affects you, because propoxyphene can make you sleepy. Do not take more of the drug than your doctor prescribed. Dependence has occurred when patients have taken propoxyphene for a long period of time at doses greater than recommended.

    The rest of this leaflet gives you more information about propoxyphene. Please read it and keep it for further use.

    Uses for Propoxyphene

    Products containing propoxyphene are used for the relief of mild to moderate pain. Products which contain propoxyphene plus acetaminophen are prescribed for the relief of pain or pain associated with fever.

    Before taking Propoxyphene

    Make sure your doctor knows if you have ever had an allergic reaction to propoxyphene or acetaminophen.

    The effect of propoxyphene in children under 12 has not been studied. Therefore, use of the drug in this age group is not recommended.

    How to take Propoxyphene

    Follow your doctor’s directions exactly. Do not increase the amount you take without your doctor’s approval. If you miss a dose of the drug, do not take twice as much the next time.

    Pregnancy

    Do not take propoxyphene during pregnancy unless your doctor knows you are pregnant and specifically recommends its use. Cases of temporary dependence in the newborn have occurred when the mother has taken propoxyphene consistently in the weeks before delivery. As a general principle, no drug should be taken during pregnancy unless it is clearly necessary.

    General Cautions

    Heavy use of alcohol with propoxyphene is hazardous and may lead to overdosage symptoms (see “Overdosage” below); THEREFORE, LIMIT YOUR INTAKE OF ALCOHOL WHILE TAKING PROPOXYPHENE.

    Combinations of excessive doses of propoxyphene, alcohol, and tranquilizers are dangerous. Make sure your doctor knows if you are taking tranquilizers, sleep aids, antidepressant drugs, antihistamines, or any other drugs that make you sleepy. The use of these drugs with propoxyphene increases their sedative effects and may lead to overdosage symptoms, including death (see “Overdosage” below).

    Propoxyphene may cause drowsiness or impair your mental and/or physical abilities; therefore, use caution when driving a vehicle or operating dangerous machinery. DO NOT perform any hazardous task until you have seen your response to this drug.

    Propoxyphene may increase the concentration in the body of medications such as anticoagulants (“blood thinners”), antidepressants, or drugs used for epilepsy. The result may be excessive or adverse effects of these medications. Make sure your doctor knows if you are taking any of these medications.

    Dependence

    You can become dependent on propoxyphene if you take it in higher than recommended doses over a long period of time. Dependence is a feeling of need for the drug and a feeling that you cannot perform normally without it.

    Overdosage

    An overdose of propoxyphene, alone or in combination with other drugs, including alcohol, may cause weakness, difficulty in breathing, confusion, anxiety, and more severe drowsiness and dizziness. Extreme overdosage may lead to unconsciousness and death.

    If the propoxyphene product contains acetaminophen, the overdosage symptoms include nausea, vomiting, lack of appetite, and abdominal pain. Liver damage may occur even after symptoms disappear. Death can occur days later.

    In any suspected overdosage situation, contact your doctor or nearest hospital emergency room. GET EMERGENCY HELP IMMEDIATELY.

    KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.

    Possible Side Effects

    When propoxyphene is taken as directed, side effects are infrequent. Among those reported are drowsiness, dizziness, nausea, and vomiting. If these effects occur, it may help if you lie down and rest.

    Less frequently reported side effects are constipation, abdominal pain, skin rashes, light-headedness, headache, weakness, minor visual disturbances, and feelings of elation or discomfort.

    If side effects occur and concern you, contact your doctor.

    Other information

    The safe and effective use of propoxyphene depends on your taking it exactly as directed. This drug has been prescribed specifically for you and your present condition. Do not give this drug to others who may have similar symptoms. Do not use it for any other reason.

    If you would like more information about propoxyphene, ask your doctor or pharmacist. They have a more technical leaflet (professional labeling) you may read.

    Watson Laboratories, Inc.
    Corona, CA 92880 USA

    30163-3
    Rev: September 2003

    Close
  • INGREDIENTS AND APPEARANCE
    PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN 
    propoxyphene hydrochloride and acetaminophen tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0591-0714
    Route of Administration ORAL DEA Schedule CIV    
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Propoxyphene Hydrochloride (Propoxyphene) 65 mg
    Acetaminophen (Acetaminophen) 650 mg
    Inactive Ingredients
    Ingredient Name Strength
    corn starch  
    crospovidone  
    D & C Red No. 30 alumium lake  
    D & C Yellow No. 10 alumium lake  
    hypromellose  
    magnesium stearate  
    microcrystalline cellulose  
    polarcrillin sodium  
    polyethylene glycol  
    polysorbate 80  
    povidone  
    pregelatinized starch  
    stearic acid  
    titanium dioxide  
    Product Characteristics
    Color ORANGE Score no score
    Shape OVAL (oblong) Size 19mm
    Flavor Imprint Code 714;65;650;WATSON
    Contains     
    Coating false Symbol false
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0591-0714-01 100 in 1 BOTTLE
    2 NDC:0591-0714-05 500 in 1 BOTTLE
    Labeler - Watson Laboratories, Inc.
    Close